文献速递主动脉疾病颈动脉与弓上血管

开窗主动脉弓腔内修复术治疗累及石丸2区和3区的主动脉疾病

Fenestrated Aortic Arch Endovascular Repair for Aortic Diseases Extending to Ishimaru Zones 2 and 3.
PubMed 文献 · J Endovasc Ther · 2025-03-18

单中心回顾性分析75例接受开窗主动脉弓腔内修复术(fTEVAR)以保留左颈总动脉或左锁骨下动脉、病变累及石丸2区和3区的患者,技术成功率93.3%,30天死亡8.0%、卒中5.3%;多因素分析显示左颈总动脉桥接与卒中独立相关(OR 0.2,95%CI 0.08-0.3,p<0.001),保留左锁骨下动脉似乎安全且无神经系统后果。

要点

  • fTEVAR治疗累及石丸2区和3区的主动脉疾病早期结果令人鼓舞,技术成功率93.3%。
  • 30天死亡8.0%、卒中5.3%,所有卒中均见于保留左颈总动脉的患者。
  • 左颈总动脉桥接与卒中独立相关(OR 0.2,95%CI 0.08-0.3,p<0.001)。

核心结论

  • fTEVAR治疗累及2区和3区的主动脉疾病早期结果令人鼓舞。
  • 左颈总动脉桥接似乎与更高的卒中率独立相关。
  • 保留左锁骨下动脉似乎安全,无神经系统后果。

研究设计与样本

  • 单中心回顾性分析,纳入2011年9月1日至2023年12月31日期间因保留左颈总动脉或左锁骨下动脉而接受fTEVAR的患者,遵循STROBE指南。
  • 仅使用预装开窗定制器械(Cook Medical,Bloomington,IN,USA)。
  • 共纳入75例患者,年龄72岁(IQR 13),范围48-86岁,男性66.7%。
  • 54例计划保留左锁骨下动脉,21例计划保留左颈总动脉;7例(9.3%)紧急治疗。
  • 主要结局为30天技术成功、死亡和卒中;生存率和免于二次干预率采用Kaplan-Meier估计评估。

主要发现

  • 21例(28.0%)表现为主动脉夹层,其中19例为B型。
  • 石丸2区病变扩展44例(58.7%),3区32例(42.7%)。
  • 22例患者行去分支化,其中81.8%为左颈总动脉-左锁骨下动脉旁路。
  • 技术成功率为93.3%,近端锚定区位于0区18.7%、1区70.7%、2区10.6%。
  • 30天死亡6例(8.0%),卒中4例(5.3%),其中2例(2.7%)为主要卒中;所有卒中均见于保留左颈总动脉的患者;多因素分析显示左颈总动脉桥接与卒中独立相关(OR 0.2,95%CI 0.08-0.3,p<0.001);中位随访12个月,12个月生存率85.2%(标准误4.7%),免于二次干预率75.0%(标准误6.5%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Fenestrated endovascular aortic arch repair (fTEVAR) has been successfully used for the exclusion of aortic lesions extending to distal arch. This study aimed to present the outcomes of fTEVAR for the preservation of the left common carotid artery (LCCA) or left subclavian artery (LSA) in lesions extending to Ishimaru zone 2 and 3. MATERIALS AND METHODS: A single-center retrospective analysis of patients managed with fTEVAR for the preservation of the LCCA or LSA, between September 1st, 2011 and December 31st, 2023, was conducted, following the STROBE guidelines. Only preloaded fenestrated custom-made devices (Cook Medical, Bloomington, IN, USA) were used. Primary outcomes were technical success, mortality, and stroke at 30 days. Survival and freedom from secondary intervention were assessed using Kaplan-Meier estimates. RESULTS: Seventy-five patients were included [72 years (IQR 13), range 48-86; 66.7% males]; 54 scheduled for LSA and 21 for LCCA preservation. Seven (9.3%) were treated urgently. Twenty-one (28.0%) presented with aortic dissection; 19 type B. Ishimaru zone 2 disease extension was recorded in 44 (58.7%) and zone 3 in 32 (42.7%). Debranching was performed in 22 patients: 81.8% LCCA-LSA bypass. Technical success was 93.3% with proximal landing to zone 0 in 18.7% cases, zone 1 in 70.7%, and zone 2 in 10.6%. Six (8.0%) deaths were recorded at 30-days and 4 (5.3%) strokes; 2 (2.7%) major. All strokes were diagnosed in patients with LCCA preservation. The multivariate analysis showed LCCA bridging (OR 0.2, 95% CI 0.08-0.3, p < 0.001) as independently related to stroke. The median follow-up was 12 months. The survival and freedom from secondary intervention were 85.2% [standard error (SE) 4.7%] and 75.0% (SE 6.5%) at 12 months, respectively. CONCLUSION: Patients treated by fTEVAR for diseases extending to zones 2 and 3 presented encouraging early outcomes. LCCA bridging seems to be independently related to higher stroke rate. Preservation of the LSA seems safe, without neurological consequences.Clinical ImpactFenestrated endovascular arch repair has been applied with acceptable mortality in distal aortic arch lesions. However, the published experience is limited. This retrospective study of 75 patients with disease extend to zones 2 and 3 showed encouraging early outcomes with 93.3% technical success, 8.0% mortality, and 5.3% strokes. The inclusion of the left common carotid artery to the repair was related to higher stroke rate, while the preservation of the left subclavian seems to have no neurological consequences.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Nana P, Panuccio G, Torrealba JI, et al. Fenestrated Aortic Arch Endovascular Repair for Aortic Diseases Extending to Ishimaru Zones 2 and 3. J Endovasc Ther. 2025. PMID: 40099993. doi:10.1177/15266028251324826

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。